<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02440451</url>
  </required_header>
  <id_info>
    <org_study_id>IBILI-VB-2015-02</org_study_id>
    <nct_id>NCT02440451</nct_id>
  </id_info>
  <brief_title>Rt-fMRI NF Intervention Study in ASD</brief_title>
  <acronym>NF-ASD</acronym>
  <official_title>Improving Facial Expression Identification in ASD: a Real-time fMRI Neurofeedback Approach</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Coimbra</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Coimbra</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to demonstrate that fMRI neurofeedback training improves the identification
      and comprehension of emotional facial expressions (and overall social behaviour) in subjects
      with ASD.

      The intervention setup provides structured presentation of emotional facial expressions and
      the associated tools for mental imagery. The investigators hypothesize that the
      accomplishment of the proposed competence training improves the subjects ability to
      comprehend facial expressions, identify emotions and be able to correctly express them.

      Intervention Type is a Device (brain computer interface using brain imaging signals) and the
      specific Intervention Name is Neurofeedback.

      Structure: (1) initial eligibility screening, (2) pre-intervention (first week of study,
      baseline outcome measures and additional evaluations), (3) intervention process (8 weeks),
      (4) post-intervention (outcome measures and additional evaluations), and (5) follow-up
      (outcome measures at 6 months).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Clinical research has demonstrated that ASD children have deficits in the identification and
      interpretation of the emotional and mental state of others (Baron-Cohen 2001). An important
      skill to this end (impaired in ASD patients), is to appropriately recognize and discriminate
      emotional expressions.

      The main brain regions involved in face processing the inferior occipital gyri, lateral
      portion of the fusiform gyrus (especially a region deemed the fusiform face area or FFA), and
      posterior superior temporal sulcus (pSTS) (Haxby et al. 2000). STS plays a key role on
      several basic aspects in social information processing, and deficits in ASD have been found
      associated to this region.

      The purpose of the study is to determine the effect of neurofeedback considering a social
      cognition brain region (i.e. pSTS) on the identification of facial expressions in ASD
      patients. The intervention comprehends seven BCI sessions spread over four months. The first
      four sessions are weekly, and the rest monthly. In each session, the subjects are asked to
      imagine different facial expressions and their brain activity (i.e. BOLD activation in the
      pSTS region) is interpreted and used to estimate a feedback signal.The hypothesis is that the
      training induced up-regulation of the target region, improves clinical symptoms.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2016</start_date>
  <completion_date type="Actual">September 2018</completion_date>
  <primary_completion_date type="Actual">September 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>FEEST - Facial Expression of Emotion: Stimuli and Tests</measure>
    <time_frame>8 weeks (Endpoint 1) plus 6 months follow-up</time_frame>
    <description>The Emotion Hexagon test represents the primary outcome measure. The assessment based on this test will be performed before (baseline), after the intervention - endpoint 1 (at 8 weeks) and at the 6 months follow-up. The Emotion Hexagon test uses stimuli of graded difficulty, created using computer image manipulation techniques (morphing is used to modify photographs from the Ekman and Friesen (1976) series, creating examples that lie close to or more distant from the prototype expression). The 120 test trials with unambiguous stimuli (4 pictures for each of the 6 emotions across the 5 test blocks) can be used to derive an overall (total) score out of a possible maximum of 120 expressions correctly recognized.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ATEC - Autism Treatment Evaluation Checklist</measure>
    <time_frame>8 weeks (Endpoint 1) plus 6 months follow up</time_frame>
    <description>Autism Treatment Evaluation Checklist (ATEC) evaluates the effectiveness of autism treatments - a 1-page form designed to be completed by parents or caretakers. It consists of 4 subtests: I. Speech/Language Communication (14 items, min.0-max.28); II. Sociability (20 items, min.0-max.40); III. Sensory/Cognitive Awareness (18 items, min.0-max.36); and IV. Health/Phys./Behavior (25 items, min.0-max.75). Total score (sum) ranges from min.0-max.179.
The results reported here correspond to the total ATEC score to be used for comparison at a later date. The lower the score, the fewer the problems.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VABS - Vineland Adaptive Behaviour Scale</measure>
    <time_frame>8 weeks (Endpoint 1) plus 6 months follow-up</time_frame>
    <description>The Vineland Adaptive Behaviour Scale (VABS) is a semi-structured interview designed to assess global adaptive functioning, composed by 3 main domains: Communication COM, Daily Living Skills DLS and Socialization SOC (all reported here in terms of standard scores as described in the VABS manual, i.e. mean 100 and standard deviation 15).
The Adaptive Behaviour Composite ABC (total score, also reported here) is the sum of the raw scores from the three main domains. These are transformed in standard scores (m.=100;std.=15).
The higher the score, better is the adaptive behavior.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>POMS - Profile of Mood States</measure>
    <time_frame>8 weeks (Endpoint 1) plus 6 months follow-up</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>HADS - Hospital Anxiety &amp; Depression Scale</measure>
    <time_frame>8 weeks (Endpoint 1) plus 6 months follow-up</time_frame>
    <description>24-item scale (7 depression &amp; 7 anxiety items)</description>
  </other_outcome>
  <other_outcome>
    <measure>BDI - Beck Depression Inventory</measure>
    <time_frame>8 weeks (Endpoint 1) plus 6 months follow-up</time_frame>
    <description>21-item measure of clinical depression</description>
  </other_outcome>
  <other_outcome>
    <measure>Debriefing Interview Questionnaire</measure>
    <time_frame>8 weeks (Endpoint 1)</time_frame>
    <description>Covers: strategies; general experience of the process; adverse effects;</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Autism Spectrum Disorder</condition>
  <arm_group>
    <arm_group_label>Neurofeedback using BCI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>16 (13 + 3 in case of dropoffs) ASD subjects</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Neurofeedback using BCI</intervention_name>
    <description>This group will undergo five sessions of neurofeedback intervention in the fMRI scanner. Each subject will also undergo neuropsychological evaluations before the first neurofeedback session (week 0) and after the last neurofeedback session (week 7). The first four sessions are weekly while the last one is one month later. The intervention will take a total of four months. Follow up will be performed in the the first week and 6 months after the last intervention session.</description>
    <arm_group_label>Neurofeedback using BCI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Positive diagnostic results for ASD in:

        Autism Diagnostic Interview-Revised; Autism Diagnostic Observation Schedule; The Diagnostic
        and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria.

        Exclusion Criteria:

          -  Global Intelligence Quotient &lt; 80

          -  Associated medical condition such as epilepsy, neurocutaneous or other genetic
             syndromes, or other usual comorbidity in ASD samples
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Miguel S Castelo-Branco, M. D., PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>IBILI - Institute for Biomedical Imaging in Life Sciences</affiliation>
  </overall_official>
  <reference>
    <citation>Baron-Cohen S, Wheelwright S, Hill J, Raste Y, Plumb I. The &quot;Reading the Mind in the Eyes&quot; Test revised version: a study with normal adults, and adults with Asperger syndrome or high-functioning autism. J Child Psychol Psychiatry. 2001 Feb;42(2):241-51.</citation>
    <PMID>11280420</PMID>
  </reference>
  <reference>
    <citation>Haxby JV, Hoffman EA, Gobbini MI. The distributed human neural system for face perception. Trends Cogn Sci. 2000 Jun;4(6):223-233.</citation>
    <PMID>10827445</PMID>
  </reference>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>April 24, 2015</study_first_submitted>
  <study_first_submitted_qc>May 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2015</study_first_posted>
  <results_first_submitted>October 11, 2018</results_first_submitted>
  <results_first_submitted_qc>October 11, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">November 13, 2018</results_first_posted>
  <last_update_submitted>January 29, 2019</last_update_submitted>
  <last_update_submitted_qc>January 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Coimbra</investigator_affiliation>
    <investigator_full_name>Miguel Castelo-Branco</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Autism Spectrum Disorder</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 14, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/51/NCT02440451/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 14, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/51/NCT02440451/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The participants, mainly recruited on a collaborative effort between the Pediatrics Hospital of Coimbra and local ASD associations, were invited for an fMRI neurofeedback feasibility clinical trial study in ASD. All participants had normal or corrected to normal vision. ). The first participant was recruited in February 2016.</recruitment_details>
      <pre_assignment_details>There was no significant events after participant enrollment, before group assignment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Neurofeedback Using BCI</title>
          <description>16 (13 + 3 in case of dropoffs) ASD subjects
Neurofeedback (BCI using neuroimaging): This group will undergo five sessions of neurofeedback intervention in the fMRI scanner. Each subject will also undergo neuropsychological evaluations before the first neurofeedback session (week 0) and after the last neurofeedback session (week 7). The first four sessions are weekly while the last one is one month later. The intervention will take a total of four months. Follow up will be performed in the the first week and 6 months after the last intervention session.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The number of participants is similar to the assigned in the participant flow.</population>
      <group_list>
        <group group_id="B1">
          <title>Neurofeedback Using BCI</title>
          <description>16 (13 + 3 in case of dropoffs) ASD subjects
Neurofeedback (BCI using neuroimaging): This group will undergo five sessions of neurofeedback intervention in the fMRI scanner. Each subject will also undergo neuropsychological evaluations before the first neurofeedback session (week 0) and after the last neurofeedback session (week 7). The first four sessions are weekly while the last one is one month later. The intervention will take a total of four months. Follow up will be performed in the the first week and 6 months after the last intervention session.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19.92" lower_limit="16.83" upper_limit="29.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Portugal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>FEEST - Facial Expression of Emotion: Stimuli and Tests</title>
          <description>The Emotion Hexagon Test from Facial expressions of emotion: Stimuli and Test (FEEST) represents the primary outcome measure. The test uses 30 computer-manipulated images of faces from the Ekman and Friesen series to test recognition of basic emotions - anger, disgust, fear, happiness, sadness and surprise.Here we report the total score. The results are converted to a score of min.0 and max.120 correct for recognition of all six emotions. The higher the score, better is the ability to recognize emotions.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="98" spread="19.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ATEC - Autism Treatment Evaluation Checklist</title>
          <description>Autism Treatment Evaluation Checklist (ATEC) evaluates the effectiveness of autism treatments - a 1-page form designed to be completed by parents or caretakers. It consists of 4 subtests: I. Speech/Language Communication (14 items, min.0-max.28); II. Sociability (20 items, min.0-max.40); III. Sensory/Cognitive Awareness (18 items, min.0-max.36); and IV. Health/Phys./Behavior (25 items, min.0-max.75). Total score (sum) ranges from min.0-max.179.
The results reported here correspond to the total ATEC score to be used for comparison at a later date. The lower the score, the fewer the problems.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.6" spread="13.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>VABS - Vineland Adaptive Behaviour Scale</title>
          <description>The Vineland Adaptive Behaviour Scale (VABS) is a semi-structured interview designed to assess global adaptive functioning, composed by 3 main domains: Communication COM, Daily Living Skills DLS and Socialization SOC (all reported here in terms of standard scores as described in the VABS manual, i.e. mean 100 and standard deviation 15).
The Adaptive Behaviour Composite ABC (total score, also reported here) is the sum of the raw scores from the three main domains. These are transformed in standard scores (m.=100;std.=15).
The higher the score, better is the adaptive behavior.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Baseline [VABS COM]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70.6" spread="15.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline [VABS DLS]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74" spread="17.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline [VABS SOC]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.4" spread="14.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline [VABS ABC]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.4" spread="13.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>FEEST - Facial Expression of Emotion: Stimuli and Tests</title>
        <description>The Emotion Hexagon test represents the primary outcome measure. The assessment based on this test will be performed before (baseline), after the intervention - endpoint 1 (at 8 weeks) and at the 6 months follow-up. The Emotion Hexagon test uses stimuli of graded difficulty, created using computer image manipulation techniques (morphing is used to modify photographs from the Ekman and Friesen (1976) series, creating examples that lie close to or more distant from the prototype expression). The 120 test trials with unambiguous stimuli (4 pictures for each of the 6 emotions across the 5 test blocks) can be used to derive an overall (total) score out of a possible maximum of 120 expressions correctly recognized.</description>
        <time_frame>8 weeks (Endpoint 1) plus 6 months follow-up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Neurofeedback Using BCI</title>
            <description>16 (13 + 3 in case of dropoffs) ASD subjects
Neurofeedback (BCI using neuroimaging): This group will undergo five sessions of neurofeedback intervention in the fMRI scanner. Each subject will also undergo neuropsychological evaluations before the first neurofeedback session (week 0) and after the last neurofeedback session (week 7). The first four sessions are weekly while the last one is one month later. The intervention will take a total of four months. Follow up will be performed in the the first week and 6 months after the last intervention session.</description>
          </group>
        </group_list>
        <measure>
          <title>FEEST - Facial Expression of Emotion: Stimuli and Tests</title>
          <description>The Emotion Hexagon test represents the primary outcome measure. The assessment based on this test will be performed before (baseline), after the intervention - endpoint 1 (at 8 weeks) and at the 6 months follow-up. The Emotion Hexagon test uses stimuli of graded difficulty, created using computer image manipulation techniques (morphing is used to modify photographs from the Ekman and Friesen (1976) series, creating examples that lie close to or more distant from the prototype expression). The 120 test trials with unambiguous stimuli (4 pictures for each of the 6 emotions across the 5 test blocks) can be used to derive an overall (total) score out of a possible maximum of 120 expressions correctly recognized.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Endpoint 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.27" spread="19.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.79" spread="20.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ATEC - Autism Treatment Evaluation Checklist</title>
        <description>Autism Treatment Evaluation Checklist (ATEC) evaluates the effectiveness of autism treatments - a 1-page form designed to be completed by parents or caretakers. It consists of 4 subtests: I. Speech/Language Communication (14 items, min.0-max.28); II. Sociability (20 items, min.0-max.40); III. Sensory/Cognitive Awareness (18 items, min.0-max.36); and IV. Health/Phys./Behavior (25 items, min.0-max.75). Total score (sum) ranges from min.0-max.179.
The results reported here correspond to the total ATEC score to be used for comparison at a later date. The lower the score, the fewer the problems.</description>
        <time_frame>8 weeks (Endpoint 1) plus 6 months follow up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Neurofeedback Using BCI</title>
            <description>16 (13 + 3 in case of dropoffs) ASD subjects
Neurofeedback (BCI using neuroimaging): This group will undergo five sessions of neurofeedback intervention in the fMRI scanner. Each subject will also undergo neuropsychological evaluations before the first neurofeedback session (week 0) and after the last neurofeedback session (week 7). The first four sessions are weekly while the last one is one month later. The intervention will take a total of four months. Follow up will be performed in the the first week and 6 months after the last intervention session.</description>
          </group>
        </group_list>
        <measure>
          <title>ATEC - Autism Treatment Evaluation Checklist</title>
          <description>Autism Treatment Evaluation Checklist (ATEC) evaluates the effectiveness of autism treatments - a 1-page form designed to be completed by parents or caretakers. It consists of 4 subtests: I. Speech/Language Communication (14 items, min.0-max.28); II. Sociability (20 items, min.0-max.40); III. Sensory/Cognitive Awareness (18 items, min.0-max.36); and IV. Health/Phys./Behavior (25 items, min.0-max.75). Total score (sum) ranges from min.0-max.179.
The results reported here correspond to the total ATEC score to be used for comparison at a later date. The lower the score, the fewer the problems.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Endpoint 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32" spread="14.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.64" spread="8.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>VABS - Vineland Adaptive Behaviour Scale</title>
        <description>The Vineland Adaptive Behaviour Scale (VABS) is a semi-structured interview designed to assess global adaptive functioning, composed by 3 main domains: Communication COM, Daily Living Skills DLS and Socialization SOC (all reported here in terms of standard scores as described in the VABS manual, i.e. mean 100 and standard deviation 15).
The Adaptive Behaviour Composite ABC (total score, also reported here) is the sum of the raw scores from the three main domains. These are transformed in standard scores (m.=100;std.=15).
The higher the score, better is the adaptive behavior.</description>
        <time_frame>8 weeks (Endpoint 1) plus 6 months follow-up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Neurofeedback Using BCI</title>
            <description>16 (13 + 3 in case of dropoffs) ASD subjects
Neurofeedback (BCI using neuroimaging): This group will undergo five sessions of neurofeedback intervention in the fMRI scanner. Each subject will also undergo neuropsychological evaluations before the first neurofeedback session (week 0) and after the last neurofeedback session (week 7). The first four sessions are weekly while the last one is one month later. The intervention will take a total of four months. Follow up will be performed in the the first week and 6 months after the last intervention session.</description>
          </group>
        </group_list>
        <measure>
          <title>VABS - Vineland Adaptive Behaviour Scale</title>
          <description>The Vineland Adaptive Behaviour Scale (VABS) is a semi-structured interview designed to assess global adaptive functioning, composed by 3 main domains: Communication COM, Daily Living Skills DLS and Socialization SOC (all reported here in terms of standard scores as described in the VABS manual, i.e. mean 100 and standard deviation 15).
The Adaptive Behaviour Composite ABC (total score, also reported here) is the sum of the raw scores from the three main domains. These are transformed in standard scores (m.=100;std.=15).
The higher the score, better is the adaptive behavior.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Endpoint 1 [VABS COM]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.87" spread="14.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endpoint 1 [VABS DLS]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.93" spread="16.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endpoint 1 [VABS SOC]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.73" spread="16.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endpoint 1 [VABS ABC]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.13" spread="15.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months follow-up [VABS COM]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.79" spread="13.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months follow-up [VABS DLS]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.14" spread="17.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months follow-up [VABS SOC]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.43" spread="15.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months follow-up [VABS ABC]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.57" spread="13.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>POMS - Profile of Mood States</title>
        <time_frame>8 weeks (Endpoint 1) plus 6 months follow-up</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>HADS - Hospital Anxiety &amp; Depression Scale</title>
        <description>24-item scale (7 depression &amp; 7 anxiety items)</description>
        <time_frame>8 weeks (Endpoint 1) plus 6 months follow-up</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>BDI - Beck Depression Inventory</title>
        <description>21-item measure of clinical depression</description>
        <time_frame>8 weeks (Endpoint 1) plus 6 months follow-up</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Debriefing Interview Questionnaire</title>
        <description>Covers: strategies; general experience of the process; adverse effects;</description>
        <time_frame>8 weeks (Endpoint 1)</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months (from baseline until 6 months follow-up assessment)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Neurofeedback Using BCI</title>
          <description>16 (13 + 3 in case of dropoffs) ASD subjects
Neurofeedback (BCI using neuroimaging): This group will undergo five sessions of neurofeedback intervention in the fMRI scanner. Each subject will also undergo neuropsychological evaluations before the first neurofeedback session (week 0) and after the last neurofeedback session (week 7). The first four sessions are weekly while the last one is one month later. The intervention will take a total of four months. Follow up will be performed in the the first week and 6 months after the last intervention session.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Prof. Dr. Miguel Castelo-Branco</name_or_title>
      <organization>University of Coimbra</organization>
      <phone>+351239790000</phone>
      <email>mcbranco@fmed.uc.pt</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

